Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.65 CAD | -1.69% | -6.06% | +17.72% |
Apr. 08 | HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA | CI |
Mar. 14 | Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 603.1 | 448.6 | 385 | 234.8 | 95.55 | 108.3 | - | - |
Enterprise Value (EV) 1 | 675.7 | 448.6 | 385 | 234.8 | 95.55 | 108.3 | 108.3 | 108.3 |
P/E ratio | -29.3 x | -29.4 x | -28.9 x | -9.93 x | -3.51 x | -6.33 x | -9.44 x | -11.7 x |
Yield | - | - | - | - | - | 4.36% | - | - |
Capitalization / Revenue | 11.1 x | 8 x | 6.42 x | 3.82 x | 1.51 x | 1.69 x | 1.47 x | 1.27 x |
EV / Revenue | 11.1 x | 8 x | 6.42 x | 3.82 x | 1.51 x | 1.69 x | 1.47 x | 1.27 x |
EV / EBITDA | 19.1 x | 18.6 x | 14.6 x | 9.85 x | 4.54 x | 5.34 x | 4.37 x | 3.43 x |
EV / FCF | - | 48.2 x | 30.6 x | 13.9 x | - | 12 x | 4.23 x | 3.42 x |
FCF Yield | - | 2.07% | 3.26% | 7.2% | - | 8.31% | 23.6% | 29.3% |
Price to Book | - | 2.66 x | - | 1.87 x | - | - | - | - |
Nbr of stocks (in thousands) | 30,742 | 31,744 | 32,451 | 32,384 | 32,071 | 31,886 | - | - |
Reference price 2 | 19.62 | 14.13 | 11.86 | 7.250 | 2.979 | 3.397 | 3.397 | 3.397 |
Announcement Date | 3/19/20 | 3/18/21 | 3/17/22 | 3/16/23 | 3/14/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 54.16 | 56.11 | 60.01 | 61.47 | 63.07 | 64.08 | 73.43 | 85.5 |
EBITDA 1 | 31.64 | 24.14 | 26.33 | 23.83 | 21.05 | 20.28 | 24.8 | 31.6 |
EBIT 1 | -4.628 | -12.09 | -6.284 | -13.5 | -10.35 | -12.4 | -8.7 | -0.4 |
Operating Margin | -8.55% | -21.54% | -10.47% | -21.96% | -16.41% | -19.35% | -11.85% | -0.47% |
Earnings before Tax (EBT) 1 | - | -16.3 | -11.81 | -23.72 | -27.8 | -21.7 | -18.5 | -10.2 |
Net income 1 | -19.55 | -15.33 | -13.12 | -23.6 | -27.53 | -20.6 | -17.6 | -9.1 |
Net margin | -36.1% | -27.32% | -21.86% | -38.39% | -43.65% | -32.15% | -23.97% | -10.64% |
EPS 2 | -0.6700 | -0.4800 | -0.4100 | -0.7300 | -0.8500 | -0.5367 | -0.3600 | -0.2900 |
Free Cash Flow 1 | - | 9.308 | 12.56 | 16.9 | - | 9 | 25.6 | 31.7 |
FCF margin | - | 16.59% | 20.93% | 27.49% | - | 14.05% | 34.86% | 37.08% |
FCF Conversion (EBITDA) | - | 38.56% | 47.7% | 70.92% | - | 44.39% | 103.23% | 100.32% |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | 0.1480 | - | - |
Announcement Date | 3/19/20 | 3/18/21 | 3/17/22 | 3/16/23 | 3/14/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 15.06 | 15.69 | 14.56 | 15.53 | 15.7 | 15.68 | 14.76 | 16.42 | 16.04 | 15.86 | 14.68 | 15.68 | 16.3 | 17.4 | 17.4 |
EBITDA 1 | 6.923 | 6.182 | 6.316 | 6.158 | 6.016 | 5.337 | 5.079 | 5.505 | 5.128 | 5.34 | 4.45 | 4.9 | 5.25 | 5.95 | 5.5 |
EBIT 1 | -0.336 | -2.392 | -2.886 | -3.561 | -2.943 | -4.107 | -3.185 | -2.998 | -3.06 | -1.106 | -3.4 | -3.3 | -3 | -2.7 | -2.5 |
Operating Margin | -2.23% | -15.25% | -19.83% | -22.93% | -18.74% | -26.2% | -21.58% | -18.26% | -19.08% | -6.97% | -23.17% | -21.05% | -18.4% | -15.52% | -14.37% |
Earnings before Tax (EBT) 1 | -1.792 | -3.517 | -3.551 | -9.146 | -4.501 | -6.524 | -5.832 | -9.32 | -7.325 | -5.326 | -5.8 | -5.6 | -5.4 | -5 | -5 |
Net income 1 | -1.979 | -4.188 | -3.616 | -9.143 | -4.41 | -6.429 | -5.792 | -9.437 | -6.901 | -5.401 | -5.5 | -5.3 | -5.1 | -4.8 | -4.7 |
Net margin | -13.14% | -26.69% | -24.84% | -58.87% | -28.08% | -41.01% | -39.25% | -57.48% | -43.03% | -34.05% | -37.48% | -33.81% | -31.29% | -27.59% | -27.01% |
EPS 2 | -0.0600 | -0.1300 | -0.1100 | -0.2800 | -0.1400 | -0.2000 | -0.1800 | -0.2900 | -0.2100 | -0.1700 | -0.1850 | -0.1700 | -0.1500 | -0.1300 | -0.1500 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/4/21 | 3/17/22 | 5/5/22 | 8/11/22 | 11/10/22 | 3/16/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/14/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | 72.6 | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 2.294 x | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | 9.31 | 12.6 | 16.9 | - | 9 | 25.6 | 31.7 |
ROE (net income / shareholders' equity) | - | -8.83% | - | -16.5% | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | 5.320 | - | 3.870 | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | - | 0.94 | - | 0.05 | - | 2 | 2 | 2 |
Capex / Sales | - | 1.67% | - | 0.07% | - | 3.12% | 2.72% | 2.34% |
Announcement Date | 3/19/20 | 3/18/21 | 3/17/22 | 3/16/23 | 3/14/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.72% | 108M | |
+17.35% | 71.39B | |
+5.38% | 8.59B | |
+6.69% | 8.19B | |
-20.96% | 7.91B | |
+0.49% | 4.54B | |
+17.12% | 4.31B | |
-3.38% | 3.93B | |
-2.61% | 3.86B | |
+22.08% | 3.64B |
- Stock Market
- Equities
- HLS Stock
- Financials HLS Therapeutics Inc.